Phio Pharmaceuticals
PHIO
10 hedge funds and large institutions have $748K invested in Phio Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
45% more capital invested
Capital invested by funds: $516K → $748K (+$232K)
11% more funds holding
Funds holding: 9 → 10 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$414K |
| 2 |
SG Americas Securities
New York
|
+$296K |
| 3 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
+$14.8K |
| 4 |
IP
Intellectus Partners
San Francisco,
California
|
+$14.8K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MA
MYDA Advisors
Woodmere,
New York
|
-$134K |
| 2 |
Morgan Stanley
New York
|
-$29.6K |
| 3 |
VF
Virtu Financial
New York
|
-$29.6K |
| 4 |
FAAS
First Allied Advisory Services
San Diego,
California
|
-$14.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$14.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $325K | +$414K | +28 | New |
|
|
2
SG Americas Securities
New York
| $228K | +$296K | +20 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $50K | +$14.8K | +1 | +33% |
|
|
DS
4
DRW Securities
Chicago,
Illinois
| $37K | – | – | – |
|
|
VF
5
Virtu Financial
New York
| $23K | -$29.6K | -2 | -50% |
|
|
FAAS
6
First Allied Advisory Services
San Diego,
California
| $22K | -$14.8K | -1 | -33% |
|
7
HighTower Advisors
Chicago,
Illinois
| $19K | – | – | – |
|
|
IP
8
Intellectus Partners
San Francisco,
California
| $19K | +$14.8K | +1 | +100% |
|
|
9
Morgan Stanley
New York
| $11K | -$29.6K | -2 | -67% |
|
|
EDRH
10
Edmond de Rothschild Holding
Chambesy,
Switzerland
| $9K | +$14.8K | +1 | New |
|
|
11
UBS Group
Zurich,
Switzerland
| $3K | -$14.8K | -1 | Closed |
|
12
BlackRock
New York
| $2K | – | – | – |
|
|
BDWM
13
Brewin Dolphin Wealth Management
Conskleagh, Dublin,
Ireland
| $2 | – | – | – |
|
|
MA
14
MYDA Advisors
Woodmere,
New York
| – | -$134K | -7 | Closed |
|
|
FC
15
Ferris Capital
Marlborough,
Massachusetts
| – | -$1K | – | – |
|
PHIO Hedge Fund Activity: Q2 2018 in Review
10 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q2 2018, worth a combined $748K — up 45% from $516K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new PHIO positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $414K. The largest seller was MYDA Advisors, exiting entirely with an estimated $134K sold.
- 10 institutional investors held Phio Pharmaceuticals (PHIO) as of Q2 2018, up from 9 in Q1 2018.
- Funds reported $748K of Phio Pharmaceuticals stock for Q2 2018, up 45% quarter-over-quarter.
- 3 funds opened new Phio Pharmaceuticals positions in Q2 2018 and 2 closed out, a net change of +1 holder.
- The largest Phio Pharmaceuticals buyer in Q2 2018 was Sabby Management, an estimated $414K added.
- The largest Phio Pharmaceuticals seller in Q2 2018 was MYDA Advisors, an estimated $134K sold.
Based on aggregated 13F filings for Q2 2018.